INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of February 7, 2025 Lead Plaintiff Deadline in the Kyverna Therapeutics, Inc. (KYTX) Securities Class Action – Investors With Signifi...
Kyverna Therapeutics, Inc. (KYTX)
Company Research
Source: GlobeNewswire
ATLANTA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX). The lawsuit alleges that the Company’s Offering Documents issued in connection with its IPO were negligently prepared because Defendants failed to disclose adverse data it possessed in regards to one of its clinical trials. If you bought shares of Kyverna on or after February 8, 2024 and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at?cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/kyverna-therapeutics/ to learn more. The deadline to ask the court to be appointed lead plaintiff in the case is February 7, 2025. Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous repres
Show less
Read more
Impact Snapshot
Event Time:
KYTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYTX alerts
High impacting Kyverna Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYTX
News
- Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies [Seeking Alpha]Seeking Alpha
- Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common StockGlobeNewswire
- Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.MarketBeat
- Kyverna Therapeutics (NASDAQ:KYTX) was given a new $33.00 price target on by analysts at Morgan Stanley.MarketBeat
- Kyverna Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswire
KYTX
Earnings
- 11/12/25 - Beat
KYTX
Sec Filings
- 12/18/25 - Form 8-K
- 12/18/25 - Form 424B5
- 12/17/25 - Form 4
- KYTX's page on the SEC website